<DOC>
	<DOCNO>NCT00807963</DOCNO>
	<brief_summary>The purpose study determine maximum tolerated concentration ( MTC ) bisphosphonate fix dose rHuPH20 administer SC , MTC bisphosphonate without rHuPH20 administer SC , optimal dose rHuPH20 deliver bisphosphonate SC MTC , compare PK SC administer bisphosphonate MTC optimal dose rHuPH20 bisphosphonate alone .</brief_summary>
	<brief_title>Pharmacokinetic , Safety Tolerability Study SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Male female volunteer 18 60 year age , inclusive . Intact normal skin area intend administration . Adequate venous access upper extremity . Dental examination appropriately trained professional within 14 day administration demonstrate sign , symptom , risk factor osteonecrosis jaw ( ONJ ) . Vital sign ( BP , HR , temperature , respiratory rate ) within normal range , range , assess Investigator clinically significant mutually agree Investigator Sponsor Medical Monitor subject need exclude study reason . Electrocardiogram within normal range range , assess Investigator clinically significant mutually agree Investigator Sponsor Medical Monitor subject need exclude study reason . Within 14 day prior administration , metabolic panel ( e.g. , sodium , potassium , chloride , bicarbonate , BUN , creatinine , glucose , calcium , AST , ALT , alkaline phosphatase , total bilirubin , albumin , total protein ) complete blood count within laboratory normal reference range , range , assess Investigator clinically significant mutually agree Investigator Sponsor Medical Monitor subject need exclude study laboratory value . A negative serum urine pregnancy test ( female childbearing potential ) within 14 day study drug administration . Female subject childbearing potential must agree currently practice effective birth control abstinence agree continue least 30 day duration time study . Decisionmaking capacity willingness ability comply requirement full completion trial . Signed , write IRB/ECapproved informed consent . Lower extremity edema . Lower extremity pathology could interfere protocolspecified outcome assessment ( e.g. , cellulitis , lymphatic disorder prior surgery , preexist pain syndrome , auxiliary lymph node dissection , etc. ) . Creatinine clearance &lt; 60 mL/min ( CockcroftGault formula ) . Any risk factor bisphosphonaterelated renal toxicity include limited know predisposition history renal insufficiency renal failure , hypertension , diabetes mellitus , volume depletion , sepsis , paraproteinemia , subject receive know nephrotoxic drug . Dehydration Grade 2 high base NCI CTCAE V3.0 . Known parathyroid gland dysfunction disease could lower blood calcium level . Known history and/or electrocardiographic evidence atrial fibrillation . Known allergy hyaluronidase . Bisphosphonate treatment within precede six month . Known allergy intolerance bisphosphonate . Pregnancy breastfeed woman . Known clinically significant cardiovascular , gastrointestinal , hepatic , neurological , psychiatric , endocrine , cancer , HIV infection , diabetes mellitus , intercurrent illness influenza , major systemic disease would unduly risk subject 's safety interfere interpretation result . Participation study investigational drug device within 30 day enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>rHuPH20</keyword>
</DOC>